文献速递类风湿关节炎

阿巴西普在合并慢阻肺的类风湿关节炎患者中的比较安全性:一项真实世界人群观察性研究

Comparative safety of abatacept in rheumatoid arthritis with COPD: A real-world population-based observational study.
PubMed 文献 · Semin Arthritis Rheum · 2019-03-16

该研究基于美国MarketScan数据库2007至2014年数据,构建RA合并COPD的bDMARD新用户队列,将阿巴西普使用者与其他bDMARD使用者按时间条件倾向评分匹配。结果显示阿巴西普相比其他bDMARD未增加不良呼吸事件风险,组合终点HR为0.87(95%CI 0.68-1.12),不支持ASSURE试验提出的安全性信号。

要点

  • 阿巴西普相比其他bDMARD,合并COPD的RA患者不良呼吸事件组合终点HR为0.87(95%CI 0.68-1.12)。
  • 住院COPD急性加重HR为0.60(95%CI 0.32-1.11),支气管炎HR为0.80(95%CI 0.56-1.14)。
  • 住院肺炎或流感HR为1.39(95%CI 0.91-2.13),门诊肺炎或流感HR为1.05(95%CI 0.86-1.29)。

核心结论

  • 在真实世界RA合并COPD患者中,阿巴西普相比其他bDMARD未增加不良呼吸事件风险,未证实ASSURE试验的安全性信号。

研究设计与样本

  • 基于美国MarketScan数据库2007至2014年数据,构建RA合并COPD的bDMARD新用户队列,阿巴西普使用者按时间条件倾向评分与其他bDMARD使用者匹配。
  • 队列含1807例起始阿巴西普患者和3547例匹配的起始其他bDMARD患者,采用Cox模型估计调整HR及95%CI。

主要发现

  • 阿巴西普相比其他bDMARD,住院COPD急性加重、支气管炎和住院肺炎或流感组合终点HR为0.87(95%CI 0.68-1.12)。
  • 住院COPD急性加重HR为0.60(95%CI 0.32-1.11),支气管炎HR为0.80(95%CI 0.56-1.14)。
  • 住院肺炎或流感HR为1.39(95%CI 0.91-2.13),门诊肺炎或流感HR为1.05(95%CI 0.86-1.29)。

临床怎么用

  • 对于合并COPD的RA患者,选用阿巴西普时无需因ASSURE试验的呼吸安全性信号而过度顾虑,但需结合个体情况评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The ASSURE randomized trial of abatacept safety in rheumatoid arthritis (RA) reported more frequent respiratory adverse events with abatacept among the subgroup of 54 patients with chronic obstructive pulmonary disease (COPD), leading to a label warning. We assessed the risk of adverse respiratory events associated with abatacept, compared with other biologic DMARDs (bDMARDs), among patients with RA and COPD in a real-world observational setting. METHODS: We formed a prevalent new-user cohort of patients with RA and COPD treated with bDMARDs within the US-based MarketScan databases from 2007 to 2014. Abatacept users were matched on time-conditional propensity scores to users of other bDMARDs. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of adverse respiratory events comparing abatacept with other bDMARDs were estimated using the Cox model. RESULTS: The cohort included 1807 patients initiating abatacept and 3547 matched patients initiating another bDMARD. The HR of the combined endpoint of hospitalized COPD exacerbation, bronchitis and hospitalized pneumonia or influenza with abatacept relative to other bDMARDs was 0.87 (95% CI: 0.68-1.12). For hospitalized COPD exacerbation it was 0.60 (95% CI: 0.32-1.11), 0.80 (95% CI: 0.56-1.14) for bronchitis, while for pneumonia or influenza it was 1.39 (95% CI: 0.91-2.13) if hospitalized and 1.05 (95% CI: 0.86-1.29) as outpatient. CONCLUSION: This large safety study from a real world setting finds no increased risk of adverse respiratory events with abatacept compared with other bDMARDs in patients with RA and COPD. This study does not substantiate the safety signal raised by the smaller ASSURE trial.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Suissa S, Hudson M, Dell'Aniello S, et al. Comparative safety of abatacept in rheumatoid arthritis with COPD: A real-world population-based observational study. Semin Arthritis Rheum. 2019. PMID: 30979397. doi:10.1016/j.semarthrit.2019.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。